Literature DB >> 17072479

Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.

Michel V F Sucupira1, Francisco C A Mello, Eneida A Santos, Christian Niel, Valeria C Rolla, Juçara Arabe, Selma A Gomes.   

Abstract

Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers. In this population, 70% of the patients were under lamivudine treatment as a component of antiretroviral therapy. HBV DNA was detected in 14 (32%) patients. Eight out of 12 (67%) HBsAg positive samples, 3/10 (30%) anti-HBc only samples, and 3/22 (14%) anti-HBs positive samples were HBV DNA positive. HBV DNA loads, measured by real time polymerase chain reaction, were much higher in the HBsAg positive patients (mean, 2.5 x 10(9) copies/ml) than in the negative ones (HBV occult infection; mean, 2.7 x 10(5) copies/ml). Nine out of the 14 HBV DNA positive patients were under lamivudine treatment. Lamivudine resistant mutations in the polymerase gene were detected in only three patients, all of them belonging to the subgroup of five HBsAg positive, HBV DNA positive patients. A low mean HBV load (2.7 x 10(5) copies/ml) and an absence of lamivudine resistant mutations were observed among the cases of HBV occult infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072479     DOI: 10.1590/s0074-02762006000600013

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

Review 1.  Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance.

Authors:  Angelica Maldonado-Rodriguez; Ana Maria Cevallos; Othon Rojas-Montes; Karina Enriquez-Navarro; Ma Teresa Alvarez-Muñoz; Rosalia Lira
Journal:  World J Hepatol       Date:  2015-02-27

2.  Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Authors:  Stefan Reuter; Mark Oette; Frank Clemens Wilhelm; Bastian Beggel; Rolf Kaiser; Melanie Balduin; Finja Schweitzer; Jens Verheyen; Ortwin Adams; Thomas Lengauer; Gerd Fätkenheuer; Herbert Pfister; Dieter Häussinger
Journal:  Med Microbiol Immunol       Date:  2010-09-19       Impact factor: 3.402

3.  Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.

Authors:  Francisco C A Mello; Bárbara V Lago; Lia L Lewis-Ximenez; Carlos A Fernandes; Selma A Gomes
Journal:  BMC Microbiol       Date:  2012-06-06       Impact factor: 3.605

4.  Comparison of epidemiological methods for estimation of hepatitis B incidence and residual risk for blood donors in southern Brazil.

Authors:  Emil Kupek; Andrea Petry
Journal:  J Transfus       Date:  2011-05-10

5.  Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.

Authors:  Henry Bautista-Amorocho; Yeny Zulay Castellanos-Domínguez; Laura Andrea Rodríguez-Villamizar; Sindi Alejandra Velandia-Cruz; Jeysson Andrey Becerra-Peña; Ana Elvira Farfán-García
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

6.  Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.

Authors:  Marcelle Bottecchia; Francisco J D Souto; Kycia M R O; Marcia Amendola; Carlos E Brandão; Christian Niel; Selma A Gomes
Journal:  BMC Microbiol       Date:  2008-01-22       Impact factor: 3.605

7.  Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.

Authors:  Nathalia Mantovani; Maira Cicero; Luiz Claudio Santana; Carla Silveira; Eliane Pereira do Carmo; Paulo Roberto Ferreira Abrão; Ricardo Sobhie Diaz; Marcos Montani Caseiro; Shirley Vasconcelos Komninakis
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.